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Key Points
• A protein-domain fo-
cused CRISPR-Cas9
screen uncovers SPOP
as a novel HbF
repressor.
• The repressive role of
SPOP on HbF is inde-
pendent of BCL11A or
LRF but is dependent
on CUL3 activity.
Reactivation of fetal hemoglobin (HbF) production beneﬁts patients with sickle cell disease
and b-thalassemia. To identify new HbF regulators that might be amenable to pharmaco-
logic control, we screened a protein domain–focused CRISPR-Cas9 library targeting
chromatin regulators, including BTB domain–containing proteins. Speckle-type POZ protein
(SPOP), a substrate adaptor of the CUL3 ubiquitin ligase complex, emerged as a novel HbF
repressor. Depletion of SPOP or overexpression of a dominant negative version signiﬁcantly
raised fetal globin messenger RNA and protein levels with minimal detrimental effects on
normal erythroid maturation, as determined by transcriptome and proteome analyses.
SPOP controls HbF expression independently of the major transcriptional HbF repressors
BCL11A and LRF. Finally, pharmacologic HbF inducers cooperate with SPOP depletion
during HbF upregulation. Our study implicates SPOP and the CUL3 ubiquitin ligase system
in controlling HbF production in human erythroid cells and may offer new therapeutic
strategies for the treatment of b-hemoglobinopathies.
Introduction
Hemoglobin comprises a tetramer containing 2 a-type and 2 b-type subunits. The human b-type
globin gene cluster consists of an embryonic (e-globin), 2 fetal (g-globin), and 2 adult type
(d-globin and b-globin) genes. Mutations in the b-globin gene that underlie sickle cell disease
(SCD) and some types of b-thalassemia become clinically relevant after birth when the fetal genes
are silenced. Increased fetal hemoglobin (HbF) production as a result of natural genetic variation or
therapeutic intervention can lower morbidity and mortality in b-hemoglobinopathies.1,2 Although
promising strategies involving gene addition or genome editing are being pursued,3,4 their
implementation will be largely restricted to patients with access to sophisticated medical providers.
Effective HbF induction by pharmacologic means is therefore needed but remains a challenge.
BCL11A and LRF (ZBTB7A) are critical direct transcriptional repressors of the g-globin genes.5-8
However, as DNA-binding proteins with functions in multiple tissues, they remain difficult to target
pharmacologically and in an erythroid selective manner. Moreover, LRF depletion delays erythroid
differentiation.8,9 In spite of a deep understanding of the transcriptional control of the globin genes, the
regulatory circuitry outside of DNA-binding nuclear factors remains underexplored. Yet, it is clear from
targeted depletion experiments that non–DNA-binding coregulatory complexes can play pivotal roles in
HbF silencing.10,11
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To identify new and potentially druggable nuclear HbF regulators,
we screened in HUDEP-2 cells12 a library that is composed of single-
guide RNAs (sgRNAs) directed against chromatin-associated
nuclear proteins containing BTB domains, chromo domains, PWWP
domains, and PHD domains among others (supplemental data) using
an improved protein domain–based CRISPR-Cas9 platform.10,13
These domains have conserved structures and might provide
potential surfaces for docking small-molecule inhibitors. Among
;600 BTB proteins and E3 ligase components in the library, the
screen selectively identified speckle-type POZ protein (SPOP), a
substrate adaptor of the CUL3 ubiquitin ligase complex,14 as a novel
repressor of g-globin transcription.
The repressive role of SPOP on g-globin levels is at least in part
mediated by the CUL3 ubiquitin ligase complex, and disrupting
SPOP-substrate interactions by overexpressing an SPOP-dominant
negative mutant recapitulated the effect of SPOP depletion on
g-globin expression. The activity of SPOP seems to be carried out
independently of BCL11A and LRF. SPOP depletion markedly
amplified the effects of pharmacologic HbF inducers, includ-
ing pomalidomide and hydroxyurea, suggesting that SPOP
perturbation might be useful in combination with other treatment
modalities.
Materials and methods
Cell culture
HUDEP-2 cells were cultured as described previously.12 Human
primary CD341 cells were purified from peripheral blood mononu-
clear cells obtained from the University of Pennsylvania Human
Immunology Core using an MACS MicroBead kit. CD341 cells
were differentiated using a 3-phase culture system as de-
scribed previously.15 Cells were harvested at days 13 to 16 and
analyzed by HbF staining, Wright-Giemsa staining, cell surface
marker staining, RNA sequencing (RNA-seq), reverse transcriptase
quantitative polymerase chain reaction (RT-qPCR), western blot, and
high-performance liquid chromatography.
Plasmids
The Cas9 expression vector was constructed by subcloning the
59-33FLAG-tagged human codon–optimized Cas9 complemen-
tary DNA (cDNA) from Streptococcus pyogenes into a lentiviral
EFS-Cas9-P2A-Puro expression vector via the In-Fusion cloning
system. All guide RNAs (gRNAs) were inserted into a lentiviral
U6-gRNA-EFS-GFP/mCherry expression vector by BsmBI diges-
tion. Lentivirus vectors expressing short hairpin RNA (shRNA)
against human SPOP (pLKO.1-shRNA vectors) were purchased
from Sigma. Two independent clones were used: TRCN0000145047
(shRNA#3) and TRCN0000139794 (shRNA#5). The BCL11A cDNA
(from Jian Xu), mouse Spop (mSpop) cDNA (from Doris A. Stoffers),
and human SPOP (hSPOP) wild-type (WT) and mutant cDNA (from
Luca Busino) were subcloned into a lentiviral vector pSDM101-IRES-
GFP by BamHI and NdeI. 59 hemagglutinin (HA) tag was introduced
by PCR. pFLBIO-BCL11APuro plasmid was a gift from Jian Xu. SPOP
cDNAs were also subcloned into pFLBIO Puro vector by BamHI
and XbaI.
HbF staining and fluorescence-activated cell sorting
In total, 2 to 5 million cells were fixed in 0.05% glutaraldehyde
for 10 minutes, washed 3 times with phosphate-buffered saline
(PBS)/0.1% bovine serum albumin (BSA), and then permeabilized
with 0.1% Triton X-100 for 3 to 5 minutes. After 1 wash with
13 PBS/0.1% BSA, cells were stained with HbF-allophycocyanin
conjugate antibody (1:4 dilution in 13 PBS/0.1% BSA) for
30 minutes in the dark at room temperature. Cells were then
washed twice with 13 PBS/0.1% BSA. Flow cytometry was carried
out on a BD FACSCanto flow cytometry system and cell sorting
was performed on a BD FACSJazz cell sorter at the Children’s
Hospital of Philadelphia flow cytometry core.
CRISPR-Cas9 screen
The protein domain–based sgRNA library was packaged in
lentivirus. Viral titer was determined by serial dilution. HUDEP-
2-Cas9 cells were transduced with the BTB domain and histone
modification reader domain–containing proteins library at a low
multiplicity of infection (0.3) such that ;30% of cells were green
fluorescent protein positive (GFP1) (multiplicity of infection for
these studies was ;0.25). Then, 12 million cells were infected
to yield 10003 coverage of the sgRNA library in the GFP1
population. GFP1 cells were then sorted by FACS on day 2 after
infection.
GFP1 cells were then expanded in HUDEP-2 media for an
additional 6 days (total of 8 days postinfection). On day 8 after
infection, cells were transferred to differentiation media for 7 days.
After differentiation, cells were stained for HbF as indicated above,
and sorted into HbF-high (top 10%) and HbF-low (bottom 10%)
populations as previously described.16
Genomic DNA was isolated from these samples by phenol-
chloroform extraction according to a standard protocol. sgRNAs
were amplified with Phusion Flash High Fidelity Master Mix
Polymerase with the LRG F2/R2 primer pair (supplemen-
tal Table 6). Reactions were performed with 23 cycles of
amplification with 100 ng of genomic DNA as template, and
50 parallel reactions were performed to maintain sgRNA
library representation. PCR reactions were then pooled for
each sample and purified with a QIAGEN PCR purification
kit. PCR products were subjected to Illumina MiSeq library
construction and sequencing. First, PCR products (0.5-1 mg
pooled PCR product) were end repaired with T4 DNA
polymerase, DNA polymerase I, and T4 polynucleotide kinase.
Then, an A-overhang was added to the end-repaired amplicons
using Klenow DNA Pol Exo-. The A-overhang DNA fragment
was ligated with diversity-increased barcoded Illumina adap-
tors followed by 7 precapture PCR cycles with primer pair
PE-5/PE-7 (supplemental Table 6). Samples were then purified
with the QIAquick PCR purification kit. sgRNA library concen-
trations were quantified on a 2100 Bioanalyzer. The barcoded
libraries were pooled at an equal molar ratio and subjected to
massively parallel sequencing through a MiSeq instrument
using 75-bp paired-end sequencing.
The sequencing data were de-barcoded, trimmed to contain only
the sgRNA sequence, and subsequently mapped to the reference
sgRNA library without allowing any mismatches. The read counts
were calculated for each individual sgRNA and normalized to total
read counts. Normalized read counts of sgRNAs in HbF-high and
HbF-low populations were log2 transformed in R software, and
graphical representation was performed by using the R-package
ggplot2. For details, see supplemental data.
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Results
Protein domain-focused CRISPR-Cas9 screen
identifies SPOP as a potential g-globin repressor
We have previously shown that sgRNAs targeting functional protein
domains generated phenotype-altering mutations at a higher rate
than sgRNAs designed to generate null alleles.13 To identify
additional potential g-globin repressors, we designed a library of
sgRNAs targeting approximately 600 proteins covering most of the
BTB domain and histone modification reader domain–containing
proteins (6 sgRNAs per domain). This library also included 6
sgRNAs for LRF as positive controls and 50 nontargeting sgRNAs
as negative controls. This sgRNA library was cloned into the
LRG 2.1T lentiviral vector that we had previously optimized, and
then introduced into HUDEP-2 cells12 stably expressing Cas9
(Figure 1A). We stained cells using an anti-HbF antibody, sorted the
top 10% and bottom 10% of HbF-expressing cells by FACS, and
deep-sequenced the sgRNAs from each population (Figure 1B). As
expected, nontargeting sgRNAs were evenly distributed across the
HbF-high and HbF-low populations, and all 6 sgRNAs of LRF were
enriched in the HbF-high population (Figure 1C). Moreover, the
sgRNAs targeting NuRD complex subunits (CHD4, MBD2, and
MTA2) and DNMT1, which were previously reported to be required
for g-globin silencing,11 were all enriched in the HbF-high portion
(supplemental Figure 1), which validated the screen. Interestingly,
5 of 6 sgRNAs targeting SPOP were significantly enriched in
the HbF-high population, suggesting that it might function as a
repressor of g-globin (Figure 1C). To our knowledge, a role for
SPOP in g-globin gene regulation has not been previously reported.
SPOP is one of the substrate adaptors of the CUL3 ubiquitin ligase
complex that mediates ubiquitination of target proteins and, in most
cases, causes protein degradation.14,17SPOP binds to its substrates
by its N-terminal meprin and traf homology (MATH) domain and
interacts with CUL3 via its C-terminal BTB domain18 (Figure 2A).
SPOP is widely expressed across human tissues (Genotype-Tissue
Expression database). In blood, SPOP is highly enriched in erythroid
cells (BloodSpot database), and its messenger RNA (mRNA)
expression levels are comparable between fetal and adult erythro-
blasts on the basis of recently published transcriptome studies.19,20
Depletion of SPOP increases g-globin levels in
HUDEP-2 cells
To validate the results from the screen, we stably introduced 3 of
the 6 sgRNAs against the SPOP BTB domain into HUDEP-2-Cas9
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Figure 1. Protein-domain based CRISPR-Cas9 screen identifies SPOP as a novel fetal globin repressor. (A) Screening strategy. Cas9-expressing HUDEP-2 cells
were transduced with a BTB domain and histone modification reader domain-targeting sgRNA library (6 sgRNAs per domain). Edited HUDEP-2 cells were then induced to
differentiate for 7 days. Differentiated cells were stained by allophycocyanin (APC)-conjugated anti-HbF and sorted into HbF-high and HbF-low cells by FACS. Enriched
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cells and allowed the cells to undergo differentiation. All 3 SPOP
sgRNAs significantly increased the fraction of HbF-expressing
cells (Figure 2B; supplemental Figure 2). Western blots showed
that (1) SPOP protein levels declined during differentiation; (2)
GATA1 protein levels were unchanged upon SPOP depletion,
suggesting SPOP is not required for normal cell maturation; (3)
g-globin protein levels were significantly increased upon SPOP
depletion, consistent with the HbF flow cytometry results; and (4)
LRF was unchanged, but BCL11A protein levels were modestly
decreased (Figure 2C; see below).
When measuring the transcriptional effects of SPOP perturbation,
we observed robust increases in the g-globin mRNA and pre-mRNA
levels, indicating that SPOP impinges on transcriptional regulation
of g-globin. SPOP loss increased e-globin mRNA levels approxi-
mately twofold, but b-globin mRNA and pre-mRNA levels were
similar to those of controls (Figure 2D; supplemental Figure 3A-B).
Importantly, there were no notable changes in a-globin, GATA1 and
BAND3 mRNA levels (erythroid differentiation markers) (supple-
mental Figure 3C), and cell morphology (supplemental Figure 4),
suggesting that SPOP loss did not significantly impair erythroid
maturation. We also observed varying levels of HbF induction in
SPOP-depleted clonal HUDEP-2 lines (data not shown). In sum,
in the context of HUDEP-2 cells, SPOP suppresses g-globin gene
expression.
Effects of SPOP inhibition on the erythroid
transcriptome and proteome
To study the impact of SPOP depletion globally, we performed
RNA-seq using HUDEP-2 pools independently derived from 3
SPOP sgRNAs and found that global gene expression patterns
were highly similar between control and SPOP-depleted cells
(Pearson correlation coefficient above 0.95). g-Globin genes
(HBG1and HBG2) seemed to be the most strongly and significantly
increased in differentiated cells (Figure 3A). Consistent with our
qPCR results, a-globin, b-globin, GATA1, ALAS2, and BAND3
genes were comparable (Figure 3A; supplemental Figure 3B-C).
Of note, BCL11A mRNA levels were unchanged (supplemental
Figure 3D).
Given that SPOP functions as a substrate adaptor of CUL3 E3
ligase complex, SPOP loss might lead to increased protein levels of
its substrates. We performed mass spectrometry experiments to
measure protein abundances in whole-cell lysates and in nuclear
extracts from SPOP-depleted cell pools. Among ;2290 quantified
proteins from whole-cell lysates, relatively few changes in protein
levels were observed except that g-globin was strongly increased
upon SPOP depletion (supplemental Table 1). In addition, given
that SPOP loss increases transcription of g-globin (supplemental
Figure 3), we repeated the mass spectrometry analysis in nuclear
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Figure 2. SPOP depletion increases g-globin
protein and mRNA levels in HUDEP-2 cells.
(A) SPOP protein domain structure and position of
3 SPOP sgRNAs within the BTB domain. (B) HbF
flow cytometry of differentiated cells transduced
with indicated sgRNAs. Data are mean 6 standard
deviation (SD) (n 5 2). (C) Immunoblot analysis
with indicated antibodies using whole-cell lysates
from cell pools transduced with sgRNAs. (D)
g-Globin mRNA was measured by RT-qPCR; data
are plotted as percentage of g-globin over g-globin
1 b-globin gene levels. Data are mean 6 SD of at
least 2 biological replicates. Diff, differentiation;
exp, exposure. ***P , .01 from unpaired Student
t tests. BCL11A (XL), full length BCL11A.
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extracts with the goal of identifying nuclear factors directly or
indirectly controlled by SPOP. Again, among 2203 quantified
proteins, relatively few displayed altered levels (supplemental Table 2).
Among the most changed proteins was GLYR1, which we also
identified as a new SPOP substrate (see “Discussion”). However,
a-globin and b-globin abundance changed only a little or not at all
upon SPOPdepletion, consistent with the RNA-seq results (Figure 3;
supplemental Figure 5). Because of technical limitations, we
could not quantify all expressed proteins. Hence, changes in low-
abundance proteins might have escaped detection. Nevertheless,
globally, SPOP loss induced g-globin expression accompanied by
relatively few changes in the transcriptome and proteome.
Depletion of SPOP increases g-globin levels in
primary erythroid CD341 cells
We tested the repressive role of SPOP on HbF in a primary human
CD341 cell–derived culture system (Figure 4A). SPOP depletion
by 2 independent shRNAs significantly increased HbF1 cell
populations (Figure 4B; supplemental Figure 6; note donor-to-
donor variation), g-globin protein levels as shown by western blot
and high-performance liquid chromatography (Figure 4C-D), and
g-globin transcript levels by RT-qPCR (Figure 4E). Similar to
HUDEP-2 cells, GATA1 and LRF levels were unchanged but
BCL11A was reduced approximately twofold (see below). RNA-seq
analysis of SPOP-depleted cells showed that global gene
expression patterns were highly correlated between control and
SPOP-depleted cells; g-globin transcripts were increased the
most, with no significant changes in a-globin and b-globin mRNAs;
GATA1, ALAS2, and BAND3 genes were mostly unchanged; and
BCL11A and LRF transcript levels were comparable (Figure 4F;
supplemental Figure 7; supplemental Table 3). We further validated
these results by RT-qPCR (supplemental Figure 8). Importantly,
SPOP depletion did not seem to impair erythroid maturation, as
suggested by the similar transcript levels of the differentiation
makers, cell surface makers CD71 and CD235a, and cell
morphology (supplemental Figure 9). Of note, except for g-globin
genes (HBG1 and HBG2), RNA-seq and mass spectrometry data
(supplemental Tables 1-3) showed no overlap among the most
changed transcripts and proteins. Because SPOP controls protein
turnover presumably without affecting their mRNA levels, we believe
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that mRNA changes might be indirect. Furthermore, expres-
sion changes for most transcripts and proteins were modest, and
RNA-seq is more sensitive than mass spectrometry.
Increased levels of HbF reduce the propensity of SCD erythroid
cells to undergo sickling (for review, see Akinsheye et al21).1 We
depleted SPOP in CD341-derived erythroid cells from SCD
patients. Inhibition of SPOP increased g-globin to levels similar
to those found in cells from healthy donors (supplemental
Figure 10A-B; compare with Figure 4). Cells infected with SPOP
shRNAs displayed less sickling than controls when grown under
low oxygen conditions (supplemental Figure 10C-D), and the effect
size was commensurate with the degree of SPOP depletion.
SPOP-CUL3 complex represses g-globin transcription
independent of BCL11A
Because CUL3 is the core component of the SPOP-CUL3 E3
ligase complex,14 we asked whether CUL3 is involved in the
repression of HbF. Indeed, depletion of CUL3 with sgRNAs
targeting its cullin domain increased g-globin production
without affecting a-globin and b-globin levels, and had no
significant effects on GATA1, BCL11A, and LRF expression
(Figure 5A; supplemental Figures 11 and 12). SPOP protein, but
not mRNA, was increased upon CUL3 depletion (Figure 5A;
supplemental Figure 12A), consistent with previous studies
showing that SPOP-CUL3 itself can be ubiquitylated.22,23 This
upregulation of SPOP in partially CUL3-depleted cells might explain
the reduced effect size on g-globin induction when compared with
SPOP depletion. CUL3 is known to regulate cell cycle progression
by targeting cyclin E.24 Indeed, CUL3 depletion slowed cell growth
but did not ostensibly impair cell differentiation, as evidenced by
normal levels of GATA1, a-globin, and BAND3 (Figure 5A; supple-
mental Figure 12D). These data also suggest that SPOP regulates
g-globin through substrates of the CUL3-ubiquitin proteasome
pathway.
Under SPOP-deficient conditions, BCL11A was decreased at the
protein level, but not the mRNA level, in both HUDEP-2 cells and
primary erythroid CD341 cells (Figures 2C and 4C), possibly
explaining some of the effects on g-globin regulation. To test this,
we performed rescue experiments by re-introducing either BCL11A
cDNA or mSpop cDNA, which contains 2 mismatched nucleotides
upstream of the protospacer adjacent motif sequence of SPOP
gRNA#1 into SPOP-depleted cells (Figure 5C). Surprisingly,
BCL11A failed to restore g-globin repression, whereas mSpop
cDNA lowered g-globin to basal protein and mRNA levels
(Figure 5D; supplemental Figure 13). In contrast, BCL11A was able
to restore g-globin repression in BCL11A-deficient cells (supple-
mental Figure 13D-E). Moreover, if SPOP represses g-globin mainly
through BCL11A, SPOP depletion should not further increase
g-globin levels in BCL11A-deficient cells. However, loss of SPOP in
BCL11A-depleted cells further increased g-globin levels (supple-
mental Figure 14), suggesting that SPOP and BCL11A repress
g-globin transcription through distinct pathways. Finally, given that
SPOP functions as a CUL3 E3 ligase adaptor, if BCL11A were one
of its direct substrates, depletion of SPOP would be expected to
increase, but not decrease, BCL11A protein levels, and over-
expression of WT SPOP, but not derivatives unable to bind
substrates,22 should increase the ubiquitination levels of BCL11A.
However, in preliminary experiments, overexpression of WT SPOP
or mutant versions deficient for CUL3 or substrate binding did not
alter ubiquitination of BCL11A in cellular assays (data not shown).
Taken together, although SPOP depletion moderately alters
BCL11A protein amounts, these results suggest that BCL11A is
not a direct downstream effector of the SPOP-CUL3 complex
during the repression of HbF.
Overexpression of a dominant negative-acting SPOP
mutant strongly increases g-globin levels
Given its role as an E3 ligase that targets proteins to the
proteasome, we suspected that SPOP-CUL3 represses transcrip-
tion of the g-globin genes by promoting the ubiquitylation and
degradation of proteins that might function as transcriptional
activators of g-globin. To test this idea, we overexpressed a SPOP
mutant in which Tyr87 was replaced by Asn (Y87N) in the MATH
domain, which disrupts SPOP-substrate interactions.18 Indeed,
overexpression of SPOP (Y87N) strongly increased g-globin levels
and to some extent also e-globin levels without significantly
affecting a-globin and b-globin production and with no measur-
able effect on BCL11A or LRF levels (Figure 6; supplemental
Figure 15). In contrast, overexpression of wild-type SPOP had
no effect on g-globin, a-globin, and b-globin levels (Figure 6D;
supplemental Figure 15). Importantly, overexpression of SPOP
(Y87N) had no significant detrimental effect on cell maturation
(Figure 6C). In concert, our data suggest that the SPOP-CUL3
complex likely functions by promoting the turnover of proteins
involved in g-globin transcriptional regulation.
Depletion of SPOP cooperates with pomalidomide
and hydroxyurea during HbF induction
We considered whether activation of g-globin expression by SPOP
depletion could be amplified by pharmacologic agents that func-
tion via distinct pathways. Pomalidomide can induce HbF
expression,25,26 and although the mechanism of action remains
unclear, it does cause a reduction in BCL11A mRNA levels.15
Therefore, as proof of concept, we tested whether pomalidomide
might amplify the effects of SPOP depletion in HUDEP-2 cells. This
was indeed the case, because the combined treatment increased
the fraction of HbF1 cells and increased g-globin transcription more
strongly than either treatment alone (Figure 7A-B; supplemental
Figure 16A). Moreover, BCL11A transcript levels were unchanged
Figure 4. SPOP depletion increases g-globin in primary erythroid CD341 cells. (A) Schematic diagram of experimental design. (B) Representative HbF flow cytometry
of CD341 erythroid cells at day 14 of differentiation. (C) Western blot (WB) analysis with indicated antibodies for differentiated CD341 cells infected with scrambled or SPOP
shRNAs virus. (D) High-performance liquid chromatography (HPLC) analysis of cells expressing indicated shRNAs at days 15 to 16 of differentiation. Arrow indicates HbF.
(E) g-Globin mRNA was measured by RT-qPCR; data are plotted as percentage of g-globin over g-globin 1 b-globin. Data are mean 6 SD of 3 independent donors.
(F) RNA-seq analysis for CD341 cells at day 14 of differentiation. HBG1/2 indicates the combined levels of HBG1 and HBG2. The r value denotes Pearson correlation
coefficient. Log2 FPKM values were averaged from 2 independent donors. EPO, erythropoietin; HbA, adult hemoglobin, HSC, hematopoietic stem cell; IL-3, interleukin-3;
SCF, stem cell factor. **P , .05, unpaired Student t tests.
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upon SPOP deletion but were significantly decreased upon
treatment with pomalidomide (Figure 7C). In addition, although
to a lesser extent, hydroxyurea, the only US Food and Drug
Administration–approved drug for increasing HbF levels for patients
with SCDs, also amplified the effects of SPOP depletion in HUDEP-2
cells (supplemental Figure 17). Of note, these conditions did not
seem to impair cell differentiation (supplemental Figures 16B-C
and 17B). Together these data suggest that SPOP inhibition in
combination with other treatments might offer a therapeutic strategy
for HbF induction in patients with hemoglobinopathies.
Discussion
Here we identified SPOP, a substrate adaptor of the CUL3
ubiquitin E3 ligase complex, as a novel regulator of HbF expression.
Reduction in SPOP levels increased HbF production in HUDEP-2
and primary human cell cultures without substantial disruption of the
cellular transcriptome and proteome. Mechanistically, we demonstrated
that the repressive role of SPOP on g-globin is dependent on the
CUL3 ubiquitin ligase complex. Moreover, ectopic expression of a
dominant-negative form of SPOP (Y87N) unable to bind to its
substrates substantially induced HbF production. Finally, as proof of
concept, we found that combining SPOP depletion with pomalidomide
or hydroxyurea exposure induced higher HbF production than either
treatment alone.
In spite of significant efforts, the SPOP substrates relevant to
g-globin regulation remain unknown. We performed immunopre-
cipitation of an SPOP version defective for CUL3 binding (L193P)
followed by mass spectrometry and found several SPOP part-
ners (supplemental Table 8). The SPOP binding consensus motif
(w-p-S-S/T-S/T [w, nonpolar; p, polar]) has been characterized.18
Among these partners, CAPRIN1, NUP153, and GLYR1 contain
at least one such SPOP binding motif. We further tested these in
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addition to previously described SPOP substrates with functions in
the nucleus. These include BRD2, BRD4, DEK, TRIM24, SETD2,
and ATF2 (supplemental Table 9). In particular, ATF2 has been
shown to be capable of activating g-globin.27 Moreover, NRF2 has
been reported to be regulated by the CUL3 ubiquitin ligase
complex28 and might be a transcriptional activator of g-globin.29We
first tested whether SPOP regulates the amounts of any of these
proteins in erythroid cells. Only GLYR1, TRIM24, and SETD2 protein
levels were strongly upregulated upon SPOP loss or SPOP Y87N
overexpression, suggesting cell type–specific regulation of SPOP
substrates (supplemental Figure 18A-B). We further tested whether
upregulation of GLYR1, TRIM24, or SETD2 accounts for the induction
of g-globin genes. Depleting each of them individually in SPOP
knockout cells failed to restore the silencing of HbF as measured by
flow cytometry (supplemental Figures 18C and 19), suggesting that an
as yet unidentified substrate or multiple substrates convey SPOP-
mediated g-globin induction in these cells.
CUL3 interacts with BTB/POZ domain proteins such as SPOP.
Although other BTB domain–containing substrate adaptors of the
CUL3 E3 ligase were also included in our sgRNA library, SPOP
seems to be the only one involved in HbF repression. This reflects a
selective function of SPOP and is consistent with general target
selectivity of CUL3 E3 ligases via different BTB domain–containing
substrate adaptors.14 Induction of HbF upon CUL3 depletion was
less pronounced compared with SPOP loss, which may in part be
the result of the compensating effects of increased SPOP protein
levels. Moreover, in HUDEP-2 cells, CUL3 depletion impaired cell
proliferation, possibly as a result of deregulation of cyclin E,24 but
SPOP depletion did not have this effect, indicating that CUL3
targets cyclin E through another substrate-specific adaptor.
Given the central role of BCL11A in HbF silencing, it seemed likely
that the moderate decrease of BCL11A in SPOP-depleted cells
might have contributed to HbF induction. However, restoration of
BCL11A levels failed to reinstate g-globin silencing. Hence, SPOP
likely exerts its function via a different mechanism. This is also
supported by the observation that depletion of both SPOP and
BCL11A induced HbF to higher levels than either treatment alone.
Because ubiquitination can in some cases increase protein stability
or alter protein activity, we examined whether SPOP ubiquitinates
BCL11A and observed no changes upon SPOP overexpression,
again arguing against a direct functional link between SPOP and
BCL11A. Regardless, the role of SPOP in HbF silencing very likely
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involves its role as an E3 ligase, because forced expression of
SPOP (Y87N) but not SPOP WT leads to strong HbF induction.
SPOP (Y87N) expression induces g-globin to levels similar to those
observed upon SPOP depletion, but in contrast to the latter
condition, BCL11A levels remained unchanged. The reason for
this discrepancy is unclear, but these results are nevertheless
consistent with SPOP functioning via the CUL3 E3 ligase complex
and support a mechanism that does not involve BCL11A.
One means of increasing the therapeutic index is to combine
therapies that have an impact on different cellular pathways. SPOP
depletion had no effect on BCL11A mRNA levels, but because
pomalidomide is known to decrease production of BCL11 mRNA,15
we tested possible cooperativity of SPOP and pomalidomide during
HbF induction. The combination of SPOP depletion and pomalidomide
treatment induced HbF production to levels much higher than
either treatment alone. Similarly, we observed cooperativity when
combining SPOP depletion with hydroxyurea treatment, although
the underlying mechanism for cooperativity is unknown. Together,
these results support the idea that SPOP inhibition might be
combined with other treatments to augment effect size and lower
potential adverse effects through dose reduction.
The BTB domain is a druggable structure.30 Small molecules
designed to inhibit the SPOP-substrate protein interactions have
recently been reported.31 Although these molecules seem to mainly
target cytoplasmically mislocalized SPOP, this finding indicates that
SPOP-substrate protein interactions can be a potential therapeutic
target for designing small molecule inhibitors. Importantly, strong
HbF induction achieved through disrupting SPOP-substrate inter-
actions by overexpressing SPOP (Y87N) mutant further supports
this possibility. In summary, SPOP functions as a novel regulator of
HbF and offers a potential therapeutic target for monotherapy or
combination therapies for b-hemoglobinopathies.
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